EFFICACY OF ONDANSETRON AND LORAZEPAM IN CONTROLLING EMESIS ASSOCIATED WITH CYTOTOXIC CHEMOTHERAPY

A phase II study using a combination of Ondansetron and Lorazepam to t reat patients receiving either highly or moderately emetogenic chemoth erapy regimens has recently been completed. A total of 56 patients wer e enrolled and data from 53 is amenable to analysis. The overall respo nse rates were 100% and 91% for the highly and moderately emetogenic r egimens respectively, with 16 out of 20 patients (80%) and 18 out of 3 3 patients (54.5%) achieving a complete or major response respectively . Toxicity was mild and no dose modifications were necessary.